The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis
Brain · 03.09.2025 · 148 (9) · 3057-3071
DOI: 10.1093/brain/awaf170 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain, online erschienen am 06.05.2025. Verfasst von Gavin Giovannoni und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Dentistry, Blizard Institute, Queen Mary Univesity of London, London E1 2AN, UK. Hauptthemen laut MEDLINE: Multiple Sclerosis, Epstein-Barr Virus Infections, Herpesvirus 4, Human, Immunotherapy. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Epstein-Barr virus (EBV) is strongly associated with multiple sclerosis (MS). It is likely to play a causal role in the pathogenesis of MS, possibly via triggering autoimmunity through molecular mimicry, autoantigenic presentation or immune dysregulation. Alternatively, evidence supports a direct role for EBV in driving MS disease activity via latent-lytic infection cycling either within the CNS or the periphery. We highlight the recent immunological and virological findings supporting the role of active EBV infection in MS, supporting an evaluation of anti-EBV strategies as potential treatments for MS. Anti-EBV strategies include CNS penetrant small molecule anti-viral agents targeting latent and lytic infection, and immunotherapies. Immunotherapies include EBV-specific autologous or allogeneic cytotoxic T cells (CTLs) and therapeutic EBV vaccines and/or immune checkpoint inhibitors to rejuvenate and boost endogenous EBV-targeted CTL responses. In parallel, several licensed MS disease-modifying therapies may work via mechanisms targeting EBV directly or indirectly. B-cell depleting therapies have been shown to have anti-EBV activity; additionally, new strategies to target intrathecal B cells, plasmablasts and plasma cells are being explored, including high-dose anti-CD20 therapy, cladribine, proteasome inhibitors, BTK inhibitors, CNS-penetrant anti-CD20/CD19 monoclonal antibodies and CD19-targeted CAR T cells. Innovative trial designs for proof-of-concept studies to test EBV antivirals and immunotherapies in MS are needed to catalyse a wave of drug development targeting EBV as a therapeutic strategy to prevent or treat MS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine and Dentistry, Blizard Institute, Queen Mary Univesity of London, London E1 2AN, UK.
- The Albion Centre, University of Sydney, Sydney, NSW 2010, Australia.
- Warwick Cancer Research Centre, Warwick Medical School, University of Warwick, Coventry CV2 2DX, UK.
- Wolfson Institute for Biomedical Research, University College London, London WC1E 6JL, UK.
- Faculty of Medicine and Dentistry, Wolfson Institute of Population Health, Queen Mary University of London, London EC1M 6BQ, UK.
ORCID-Profile: Gavin Giovannoni, Louisa James, David Baker, Ruth Dobson
Zitieren
APA
Giovannoni, G., James, L., Adeniran, A. A., Gold, J., Young, L. S., Selwood, D. L., Baker, D., & Dobson, R. (2025). The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis. Brain, 148(9), 3057-3071. https://doi.org/10.1093/brain/awaf170
Vancouver
Giovannoni G, James L, Adeniran AA, Gold J, Young LS, Selwood DL, et al. The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis. Brain. 2025;148(9):3057-3071. doi:10.1093/brain/awaf170
BibTeX
@article{Giovannoni2025,
author = {Giovannoni, Gavin and James, Louisa and Adeniran, Adekunle A and Gold, Julian and Young, Lawrence S and Selwood, David L and Baker, David and Dobson, Ruth},
title = {The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis},
journal = {Brain},
year = {2025},
volume = {148},
number = {9},
pages = {3057--3071},
doi = {10.1093/brain/awaf170}
}
EUVIMED